Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRT8-overexpressing human umbilical cord-derived mesenchymal stem cells
- Development stage
- Preclinical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Local Injection, Intraarticular, Intrathecal
01
Overview
KRT8-overexpressing HUC-MSCs are a genetically modified form of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) engineered to overexpress keratin 8 (KRT8), an intermediate filament protein. hUC-MSCs are multipotent stromal cells with low immunogenicity and the ability to differentiate into various cell types, making them attractive for regenerative medicine and cell-based therapies[6]. Overexpression of KRT8 is intended to enhance specific biological properties or therapeutic effects, though the precise mechanism depends on the context of use. In general, hUC-MSCs exert their effects through paracrine signaling, immunomodulation, anti-inflammatory actions, and tissue repair[1][5][6]. The modification with KRT8 may further influence epithelial characteristics or resistance to apoptosis; however, detailed mechanisms specific to this engineered variant require additional published data.
- Other names
- KRT8-overexpressing human umbilical cord mesenchymal stem cellsKRT-8-overexpressing human umbilical cord mesenchymal stem cellsKRT 8-overexpressing human umbilical cord mesenchymal stem cellsKRT8-hUC-MSCsKRT-8-hUC-MSCsKRT 8-hUC-MSCs
02
Targets
KRT8 (Keratin, type II cytoskeletal 8)
Beyond the preview
Go deeper on KRT8-overexpressing human umbilical cord-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRT8-overexpressing human umbilical cord-derived mesenchymal stem cells.